ENTITY

Nuevolution AS (NUE SS)

6
Analysis
Health CareDenmark
Nuevolution AS provides pharmaceutical products and services. The Company designs and develops a small molecule lead discovery platform that represents the fragment based drug discovery technology. Nuevolution primarily operates in Denmark.
more
bullishNuevolution AS
10 Dec 2018 21:50Issuer-paid

Nuevolution - Clinical development in 2019

Nuevolution’s drug discovery platform (Chemetics) continues to receive external validation, with Amgen opting in for another oncology programme...

Share
bullishNuevolution AS
25 Sep 2018 23:10Issuer-paid

Nuevolution - Pipeline and partnerships continue to strengthen

With the completion of the up-listing to the Nasdaq Stockholm main market and the successful gross SEK110m capital raise, Nuevolution continues to...

Share
bullishNuevolution AS
15 Mar 2018 20:00Issuer-paid

Nuevolution - Pipeline and strategic execution drives prospects

Nuevolution’s 2017 was defined by internal progress of the RORγt inhibitor and BET-BD1 programmes (expected to be clinically ready in 2019). In...

Share
bullishNuevolution AS
24 Nov 2017 17:07Issuer-paid

Nuevolution - On the road to becoming a clinical company

July to September 2017 results highlight the continued progression of Nuevolution into a clinical company. Ongoing partnerships with Almirall,...

Share
bullishNuevolution AS
28 Sep 2017 22:10Issuer-paid

Defining year as partnerships progress on track

FY17 has been a defining year for Nuevolution as it looks to further validate its unique Chemetics drug discovery platform. Highlights include the...

Share
No more insights
x